Last reviewed · How we verify

NCT05525741: MFC

Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

Active, enrolled NA Last updated 4 December 2024
What this trial tests

NA trial testing Non segmental vitiligo in Skin and Connective Tissue Diseases in 59 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
19 October 2022
Primary endpoint
1 April 2023
30 June 2025

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nice
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment59
Start date19 October 2022
Primary completion1 April 2023
Estimated completion30 June 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Adults 18 to 80, any sex, with Skin and Connective Tissue Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Dysregulated Intracellular Signaling in the Pathogenesis of Vitiligo: An Update on Emerging Therapeutic Strategies.
    Marrapodi R, Marini A, Bellei B. · · 2025 · PMID 41007740 · DOI 10.3390/biomedicines13092177

Verify or expand the search:

Other recruiting trials for Skin and Connective Tissue Diseases

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525741.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing